Glucose, cholesterol, weight and interactions · Evidence guide
Berberine: evidence-based benefits, dose, forms and safety
Berberine can produce modest short-term improvements in fasting glucose, HbA1c, LDL cholesterol and triglycerides in some adults with metabolic disease, but trials are heterogeneous and do not prove fewer heart attacks, diabetes complications or longer life.
It is not ‘natural Ozempic’: a strong 2026 trial found no reduction in visceral fat or liver fat after six months. Because it can interact with medicines and poses pregnancy, newborn and transplant risks, a medication review matters more than chasing the biggest dose.1,2,3,6,7,8,9,12,13

At a glance
Berberine
- Overall evidence
- Modest short-term metabolic biomarker effects; no proven long-term clinical-outcome benefit2,8,9,10ModerateFinding: mixed results
- Blood sugar
- Fasting glucose about 0.52 mmol/L lower and HbA1c about 0.41 percentage point lower on average in one meta-analysis8ModerateFinding: small benefit
- LDL cholesterol
- About 0.46 mmol/L (18 mg/dL) lower on average across short placebo-controlled trials9ModerateFinding: small benefit
- Weight loss
- Not established; a 337-person six-month trial found no visceral-fat or liver-fat benefit1,6,7StrongFinding: no meaningful benefit
- Heart and diabetes outcomes
- No proof of fewer heart attacks, kidney failure, neuropathy, retinopathy or deaths8,9,10StrongFinding: still unknown
- Typical studied range
- Usually 900–1,500 mg/day of standard berberine, divided, for roughly 8–12 weeks8,9,11ModerateFinding: established use
- Best-supported form
- Standard berberine, commonly HCl, because most human glucose and lipid biomarker trials used it—not because it absorbs best8,9,11,14,15,16ModerateFinding: benefit supported
- Interaction risk
- Human evidence shows CYP2D6, CYP2C9 and CYP3A4 effects and increased cyclosporine exposure12,13StrongFinding: established use
Study findings describe groups, not a guaranteed result for one person.
Research and writing
LongevityMate Editorial Team
Editorial oversight
Lukas Dvorsky, FounderClinical review
Not yet assigned or claimed
Popular claims, checked
What supplement influencers are saying
These claims are included because people encounter them. Follower count, a podcast opinion and a personal routine are not scientific proof.
What is claimed
Evidence check
Contradicted. There is no head-to-head trial, the products have different pharmacology, and a 337-person six-month trial found no visceral-fat or liver-fat benefit from berberine.
What is claimed
Evidence check
Unsupported and unsafe. Modest pooled biomarker effects are not equivalence, complication prevention or permission to stop prescribed therapy; interactions and hypoglycemia require clinical review.
What is claimed
Evidence check
Not established. Trials used varied divided-dose protocols, and no robust clinical-outcome trial proves one universal meal interval or acute ‘spike blocking’ strategy.
What is claimed
Evidence check
Unsupported. Pairwise safety and outcome evidence is sparse; stacking increases attribution, hypoglycemia, hypotension and interaction problems.
What is claimed
Evidence check
Exaggerated. A five-person pharmacokinetic pilot showed higher exposure but no short-protocol glucose or insulin benefit and cannot establish equivalent dose, long-term safety or superior outcomes.
Anecdote can start a question—not answer it
A personal experience cannot show whether the supplement caused the change, how often it works or whether it is safe for someone else.